{"DataElement":{"publicId":"6117728","version":"1","preferredName":"Breast Carcinoma Progesterone Receptor Status","preferredDefinition":"The progesterone receptor status of a primary breast tumor or metastases.","longName":"BRCA_PGR_STAT","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6117721","version":"1","preferredName":"Breast Carcinoma Progesterone Receptor Status","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","longName":"2475941v1.0:2534138v1.0","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"2475941","version":"1","preferredName":"Breast Carcinoma","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"C4872","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11C95199-159B-5C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2534138","version":"1","preferredName":"Progesterone Receptor Status","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","longName":"C16149","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status","conceptCode":"C16149","definition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"21203005-5573-363C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D7C518-F8C5-65E5-E053-F662850A5C83","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6117723","version":"1","preferredName":"Progesterone Receptor Status","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)._A condition or state at a particular time.","longName":"6117723v1.0","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Positive","valueDescription":"Positive Finding","ValueMeaning":{"publicId":"5042698","version":"1","preferredName":"Positive Finding","longName":"5042698","preferredDefinition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23BCDB4E-8EE7-8E8D-E050-BB89AD432DF3","latestVersionIndicator":"Yes","beginDate":"2015-11-04","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-11-04","modifiedBy":"KUMMEROA","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682B96EA-2009-113F-E053-F662850A4B70","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Negative","valueDescription":"Negative Finding","ValueMeaning":{"publicId":"2840098","version":"1","preferredName":"Negative Finding","longName":"2840098","preferredDefinition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"635F3981-C786-F359-E040-BB89AD435EC5","latestVersionIndicator":"Yes","beginDate":"2009-02-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-02-20","modifiedBy":"KUMMEROA","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682B96EA-2014-113F-E053-F662850A4B70","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682944","version":"1","preferredName":"Unknown","longName":"5682944","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AE5-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"GDEEN","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66D615F5-B054-193F-E053-F662850A8993","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"3+","valueDescription":"Progesterone Receptor Status 3+","ValueMeaning":{"publicId":"6117724","version":"1","preferredName":"Progesterone Receptor Status 3+","longName":"6117724","preferredDefinition":"An immunohistochemical result of 3 for progesterone receptor expression that is considered positive for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status 3+","conceptCode":"C147859","definition":"An immunohistochemical result of 3 for progesterone receptor expression that is considered positive for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D615F5-B061-193F-E053-F662850A8993","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66D615F5-B07A-193F-E053-F662850A8993","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"2+","valueDescription":"Progesterone Receptor Status 2+","ValueMeaning":{"publicId":"6117725","version":"1","preferredName":"Progesterone Receptor Status 2+","longName":"6117725","preferredDefinition":"An immunohistochemical result of 2 for progesterone receptor expression that is considered intermediate for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status 2+","conceptCode":"C147858","definition":"An immunohistochemical result of 2 for progesterone receptor expression that is considered intermediate for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D615F5-B086-193F-E053-F662850A8993","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66D615F5-B09F-193F-E053-F662850A8993","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"1+","valueDescription":"Progesterone Receptor Status 1+","ValueMeaning":{"publicId":"6117726","version":"1","preferredName":"Progesterone Receptor Status 1+","longName":"6117726","preferredDefinition":"An immunohistochemical result of 1 for progesterone receptor expression that is considered weak for expression","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status 1+","conceptCode":"C147857","definition":"An immunohistochemical result of 1 for progesterone receptor expression that is considered intermediate for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D615F5-B0AB-193F-E053-F662850A8993","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66D615F5-B0C4-193F-E053-F662850A8993","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"0","valueDescription":"Progesterone Receptor Status 0","ValueMeaning":{"publicId":"6117727","version":"1","preferredName":"Progesterone Receptor Status 0","longName":"6117727","preferredDefinition":"An immunohistochemical result of 0 for progesterone receptor expression that is considered negative for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status 0","conceptCode":"C147856","definition":"An immunohistochemical result of 0 for progesterone receptor expression that is considered negative for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D615F5-B0D0-193F-E053-F662850A8993","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66D615F5-B0E9-193F-E053-F662850A8993","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6117722","version":"1","preferredName":"Progesterone Receptor Status Status","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards):A condition or state at a particular time.","longName":"C16149:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status","conceptCode":"C16149","definition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D615F5-B02A-193F-E053-F662850A8993","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D615F5-B03B-193F-E053-F662850A8993","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"BRCA_PGR_STAT","type":"USED_BY","context":"CCTG"}],"ReferenceDocuments":[{"name":"PgR status","type":"Preferred Question Text","description":"PgR status","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66E7B50F-7C49-2466-E053-F662850ABFFC","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}